DHA supplementation during pregnancy does not reduce BMI or body fat mass in children: follow-up of the DHA to Optimize Mother Infant Outcome randomized controlled trial
DHA supplementation during pregnancy does not reduce BMI or body fat mass in children: follow-up of the DHA to Optimize Mother Infant Outcome randomized controlled trial
复制标题
DOI：
10.3945/ajcn.115.126714
复制
发表时间：
2016-06-01
影响因子：
7.1
通讯作者：
Makrides, Maria
中科院分区：
文献类型：
--
作者：
Muhlhausler, Beverly S.;Yelland, Lisa N.;Makrides, Maria
背景资料：欧米茄-3（n-3）长链多不饱和脂肪酸（LCPUFA）二十二碳六烯酸（DHA）已在动物研究中证明可有效减少脂肪储存。然而，一项对人体试验的系统回顾显示，缺乏高质量的数据来支持或反驳这一假设。目的：我们试图确定母亲在怀孕后半期补充DHA是否会降低儿童的体重指数（BMI）和体脂百分比。设计：我们对参加DOMInO的母亲所生的3岁和5岁的儿童进行了随访（DHA优化母婴结局）双盲、随机对照试验，在该研究中，单胎妊娠的妇女在妊娠后半期被提供富含DHA的鱼油胶囊（800 mg DHA/d）或植物油胶囊（对照组）。主要结果是3岁和5岁时的BMI z评分和体脂百分比。产前DHA和过氧化物酶体增殖物激活受体-γ（过氧化物酶体增殖物激活受体γ）基因型之间的潜在相互作用，作为衡量的遗传易感性obesity.Results：共有1614名儿童有资格进行随访。1531名儿童（95%）获得了父母或照顾者的同意，这些儿童被纳入分析。在3岁时，DHA组儿童的BMI z评分和体脂百分比与对照组儿童无差异[BMI z评分校正平均差异：0.03（95% CI：-0.07，0.13; P = 0.61）;体脂百分比校正的平均差异：-0.26（95% CI：-0.99，0.46; P = 0.47）]或5岁[BMI z评分校正的平均差异：0.02（95%CI：-0.08，0.12; P = 0.66）;体脂百分比校正平均差异：0.11（95%CI：-0.60，0.82; P = 0.75）]。没有治疗效果被修改的PPARgamma基因型的child.Conclusion：独立的遗传易感性肥胖，母亲摄入的DHA丰富的鱼油在怀孕的下半年不影响生长或身体组成的儿童在3或5岁。本试验在www.anzctr. org. Au注册为ACTRN 1260500056906和ACTRN 12611001127998。
Background: The omega-3 (n-3) long-chain polyunsaturated fatty acid (LCPUFA) docosahexaenoic acid (DHA) has proven effective at reducing fat storage in animal studies. However, a systematic review of human trials showed a lack of quality data to support or refute this hypothesis.Objective: We sought to determine whether maternal DHA supplementation during the second half of pregnancy results in a lower body mass index (BMI) and percentage of body fat in children.Design: We conducted a follow-up at 3 and 5 y of age of children who were born to mothers enrolled in the DOMInO (DHA to Optimize Mother Infant Outcome) double-blind, randomized controlled trial, in which women with a singleton pregnancy were provided with DHA-rich fish-oil capsules (800 mg DHA/d) or vegetable-oil capsules (control group) in the second half of pregnancy. Primary outcomes were the BMI z score and pei-centage of body fat at 3 and 5 y of age. Potential interactions between prenatal DHA and the peroxisome proliferator activated receptor-gamma (PPAR gamma) genotype as a measure of the genetic predisposition to obesity were investigated.Results: A total of 1614 children were eligible for the follow-up. Parent or caregiver consent was obtained for 1531 children (95%), and these children were included in the analysis. BMI z scores and percentages of body fat of children in the DHA group did not differ from those of children in the control group at either 3 y of age [BMI z score adjusted mean difference: 0.03 (95% CI: -0.07, 0.13; P = 0.61); percentage of body fat adjusted mean difference: -0.26 (95% CI: -0.99, 0.46; P = 0.47)] or 5 y of age [BMI z score adjusted mean difference: 0.02 (95% CI: -0.08, 0.12; P = 0.66); percentage of body fat adjusted mean difference: 0.11 (95% CI: -0.60, 0.82; P = 0.75)]. No treatment effects were modified by the PPAR gamma genotype of the child.Conclusion: Independent of a genetic predisposition to obesity, maternal intake of DHA-rich fish oil during the second half of pregnancy does not affect the growth or body composition of children at 3 or 5 y of age. This trial was registered at www.anzctr.org. au as ACTRN1260500056906 and ACTRN12611001127998.